Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.


Clinical Trial Description

The American Cancer Society has estimated that colorectal cancer is the second leading cause of cancer related deaths, with 106,370 new cases diagnosed in 2004. Due to the unique nature of the hepatic circulatory system, with preferential portal venous drainage of the gastrointestinal tract, the liver is the most common site for metastatic tumor growth from a colorectal carcinoma. It is estimated that approximately 20% of patients diagnosed with colorectal cancer will present with liver involvement at the time of diagnosis, and 50% of patients will manifest metastatic involvement of the liver following resection of the primary colorectal cancer. Over one half of patients who die of colorectal cancer have liver metastases at autopsy.

The current "gold standard" in the treatment of isolated metastatic liver disease is curative hepatic resection. Only within the last 20 years has surgical resection become a viable option, as in the past it was considered unjustified due to high morbidity and mortality rates. The primary drawback to hepatic resection is the sheer number of patients for whom it is contraindicated. Only 10-20% of patients liver metastases are candidates for surgical resection, owing to factors such as tumor locations, size, extent of disease, and other medical co-morbidities.

Historically, in cases where hepatic resection was contraindicated, systemic chemotherapy was the only alternative treatment. In the last several years an increasing number of hepatic directed therapies have become available such as hepatic artery ligation, radiation, hepatic artery infusion of chemotherapy, chemoembolization, and mechanical ablation of the tumor(s).

One mechanical method of ablation involves the use of radiofrequency thermal technology, also called radiofrequency ablation (RFA). The RFA procedure involves inserting an RF electrode into the center of a hepatic tumor mass under ultrasonic or CT guidance. Radiofrequency energy is then applied through the electrode, causing a thermal injury to the surrounding tumor tissue. Currently there are two basic designs for monitoring inter-procedural progress during RFA; temperature monitoring of set points within the target tissue with thermocouples, or assessing the system-wide impedance of tissue adjacent to the deployed electrode tines. Radiofrequency ablation systems are comprised of three components: a radiofrequency generator, an active electrode, and dispersive electrodes.

To date no prospective multi-center trials have been completed which would conclusively demonstrate whether RFA is an effective adjunct to systemic chemotherapy with respect to advantages in median overall survival compared with chemotherapy alone. The primary objective of this trial is to determine overall survival for subjects with colorectal cancer and incurable metastatic liver disease who fail at least first line chemotherapy and are treated with radiofrequency ablation plus additional chemotherapy, compared to subjects receiving additional chemotherapy only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00510627
Study type Interventional
Source Boston Scientific Corporation
Contact
Status Withdrawn
Phase Phase 4
Start date August 2007
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT04970212 - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Terminated NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma Phase 1
Completed NCT02201797 - Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body N/A
Recruiting NCT03965546 - ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer Early Phase 1
Terminated NCT03998033 - Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Phase 1
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT04864054 - T-Cell Therapy (ECT204) in Adults With Advanced HCC Phase 2
Recruiting NCT05913141 - PDO/PDO-TIL/PDOTS for Drug Screen
Not yet recruiting NCT05582018 - Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures N/A
Recruiting NCT01895010 - Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE Phase 2
Withdrawn NCT05641922 - Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2) N/A
Recruiting NCT04634357 - ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04708483 - DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria N/A
Terminated NCT02787954 - Prospective Tumor Response Evaluation
Completed NCT04513457 - Chemotherapy for Resectable Colorectal Liver Metastases
Recruiting NCT01442324 - Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma N/A
Completed NCT03888859 - ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma Early Phase 1
Not yet recruiting NCT05643417 - Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy Phase 1
Recruiting NCT05240950 - Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases Phase 1